BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FlowCardia, Inc. Launches Peripheral CROSSER(R) Catheter Portfolio in the US


12/11/2007 11:19:52 AM

SUNNYVALE, Calif., Dec. 11 /PRNewswire/ -- FlowCardia, Inc., a medical device company developing a portfolio of endovascular devices for the treatment of coronary and peripheral chronic total occlusions (CTOs), announced FDA 510(k) clearance and immediate U.S. launch of the CROSSER 14P, CROSSER 14S and CROSSER 18 CTO Recanalization Catheters.

The three peripheral CROSSER Catheters are endovascular tools used by interventional radiologists, vascular surgeons and interventional cardiologists to cross CTOs to help restore blood flow to the lower legs. The CROSSER is a rapid exchange catheter delivered over standard .014" and .018" guidewires that utilizes high frequency vibration to cross CTOs allowing for subsequent debulking, balloon angioplasty and stent placement. The peripheral CROSSER Catheters were studied in the FlowCardia PATRIOT Trial.

The PATRIOT Study principle investigator, Dr. Jim Joye, commented, "After completing the clinical trial, we are looking forward to using the CROSSER in our daily practice. The device worked well in the upper leg and also proved an excellent primary therapy for crossing the more difficult, below the knee occlusions. This new endovascular line of catheters will help us cross lesions that previously could only be treated with a more invasive open surgery."

Chris Barys, Sr. Vice President of Sales said, "We are aggressively assembling our sales organization and we look forward to offering a complete, peripheral portfolio of catheters to our interventional customers. Having three CROSSER Catheter models available for use in the peripheral vasculature will allow physicians to choose the appropriate catheter based on vessel size and CTO location. This approval is significant and a true win for patients all over the world."

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture a safe and effective portfolio of CTO recanalization products. Additional information is available on the Company's Web Site at http://www.flowcardia.com.

CONTACT: Mark Page, Sr. Director, Worldwide Marketing of FlowCardia, Inc.,
+1-408-617-0352

Web site: http://www.flowcardia.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES